DekaBank Deutsche Girozentrale Has $927,000 Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

DekaBank Deutsche Girozentrale lessened its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 4.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,235 shares of the biotechnology company’s stock after selling 1,609 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Arrowhead Pharmaceuticals were worth $927,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Meeder Asset Management Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 4,629.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 3,333 shares during the period. Arizona State Retirement System raised its stake in shares of Arrowhead Pharmaceuticals by 2.4% in the second quarter. Arizona State Retirement System now owns 34,685 shares of the biotechnology company’s stock valued at $901,000 after purchasing an additional 821 shares in the last quarter. Victory Capital Management Inc. lifted its position in Arrowhead Pharmaceuticals by 67.3% in the second quarter. Victory Capital Management Inc. now owns 41,090 shares of the biotechnology company’s stock worth $1,068,000 after purchasing an additional 16,534 shares during the period. TD Asset Management Inc boosted its stake in Arrowhead Pharmaceuticals by 90.8% during the second quarter. TD Asset Management Inc now owns 54,200 shares of the biotechnology company’s stock worth $1,409,000 after buying an additional 25,800 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in Arrowhead Pharmaceuticals by 2.9% in the 2nd quarter. Rhumbline Advisers now owns 383,029 shares of the biotechnology company’s stock valued at $9,955,000 after buying an additional 10,924 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Thursday, August 1st. B. Riley reaffirmed a “buy” rating and set a $55.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, August 12th. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, September 9th. Finally, The Goldman Sachs Group initiated coverage on Arrowhead Pharmaceuticals in a research report on Wednesday, June 5th. They issued a “neutral” rating and a $31.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $44.25.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, insider Tracie Oliver sold 9,394 shares of the firm’s stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $25.28, for a total value of $237,480.32. Following the completion of the sale, the insider now owns 127,107 shares of the company’s stock, valued at $3,213,264.96. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.50% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR opened at $21.14 on Friday. The company has a market cap of $2.63 billion, a price-to-earnings ratio of -4.89 and a beta of 0.96. The stock has a fifty day moving average price of $24.92 and a two-hundred day moving average price of $25.47. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $19.44 and a 52-week high of $39.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.80). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 152.95%. During the same period in the prior year, the firm earned ($0.96) earnings per share. The firm’s revenue was down 100.0% compared to the same quarter last year. As a group, research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -4.31 EPS for the current fiscal year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.